핵의학

본문글자크기
  • [PLoS One] Prognostic Value of SUVmax Measured by Pretreatment Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Patients with Ewing Sarcoma.

    2016년 05월호
    [PLoS One] Prognostic Value of SUVmax Measured by Pretreatment Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Patients with Ewing Sarcoma.

    KIRAMS / 황재필, 임일한*

  • 출처
    PLoS One
  • 등재일
    2016 Apr 21
  • 저널이슈번호
    11(4):e0153281. doi: 10.1371/journal.pone.0153281. eCollection 2016.
  • 내용

    바로가기  >


    Abstract

    AIM:

    The aim of this retrospective study was to determine whether glucose metabolism assessed by using Fluorine-18 (F-18) fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) provides prognostic information independent of established prognostic factors in patients with Ewing sarcoma.

     

    METHODS:

    We retrospectively reviewed the medical records of 34 patients (men, 19; women, 15; mean age, 14.5 ± 9.7 years) with pathologically proven Ewing sarcoma. They had undergone F-18 FDG PET/CT as part of a pretreatment workup between September 2006 and April 2012. In this analysis, patients were classified by age, sex, initial location, size, and maximum standardized uptake value (SUVmax). The relationship between FDG uptake and survival was analyzed using the Kaplan-Meier method with the log-rank test and Cox's proportional hazards regression model.

     

    RESULTS:

    The median survival time for all 34 subjects was 999 days and the median SUV by using PET/CT was 5.8 (range, 2-18.1). Patients with a SUVmax ≤ 5.8 survived significantly longer than those with a SUVmax > 5.8 (median survival time, 1265 vs. 656 days; p = 0.002). Survival was also found to be significantly related to age (p = 0.024), size (p = 0.03), and initial tumor location (p = 0.036). Multivariate analysis revealed that a higher SUVmax (p = 0.003; confidence interval [CI], 3.63-508.26; hazard ratio [HR], 42.98), older age (p = 0.023; CI, 1.34-54.80; HR, 8.59), and higher stage (p = 0.03; CI, 1.21-43.95; HR, 7.3) were associated with worse overall survival.

     

    CONCLUSIONS:

    SUVmax measured by pretreatment F-18-FDG PET/CT can predict overall survival in patients with Ewing sarcoma. 

     

    Author information

    Hwang JP1, Lim I2,3, Kong CB4, Jeon DG4, Byun BH2, Kim BI2,3, Choi CW2,3, Lim SM2,3.

    1Department of Nuclear Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, Korea.

    2Department of Nuclear Medicine, Korea Institute of Radiological and Medical Sciences, Seoul, Korea.

    3Molecular Imaging Research Center, Korea Institute of Radiological and Medical Sciences, Seoul, Korea.

    4Department of Orthopedic Surgery, Korea Institute of Radiological and Medical Sciences, Seoul, Korea.

     

  • 연구소개
    뼈에 생기는 희귀 악성 종양인 유잉육종은 소아청소년층에서 주로 발생하기 때문에 생존기간을 예측하려는 연구가 꾸준히 진행돼 왔으나, 발생빈도가 낮아 연구에 어려움이 있었습니다. 이번 연구는 약 6년간 34명의 유잉육종 환자들을 추적 조사하여 암세포의 포도당 최대섭취량을 지표화해 생존율을 예측해낸 것으로 최대표준화섭취계수(SUVmax)가 높을수록 생존율이 짧아진다는 사실을 확인했으며 표준화섭취계수가 판정기준치인 5.8 보다 낮은 환자군의 생존기간은 1,236일, 높은 환자군의 생존기간은 627일로 나타났다. 치료전 검사를 통해 유잉육종 환자들의 생존기간과 예후를 미리 알 수 있어 맞춤 치료 등 치료계획 수립에 큰 도움이 될 것이며 이를 통해 발생연령대가 어린 유잉육종 환자의 생존율 향상에 기여할 수 있을 것으로 기대합니다.
  • 덧글달기
    덧글달기
       IP : 13.58.60.192

    등록